Drug Profile
Research programme: theranostics - Clarity Pharmaceuticals
Alternative Names: SAR-BBN; SAR-bisPSMA; SAR-Bombesin; SAR-Discovery; SAR-PSMA PET imaging - Clarity Pharmaceuticals; SAR-PSMA therapy - Clarity PharmaceuticalsLatest Information Update: 28 Oct 2021
Price :
$50
*
At a glance
- Originator Clarity Pharmaceuticals
- Class Antineoplastics; Radiopharmaceutical diagnostics; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters; Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Glioma; Ovarian cancer; Prostate cancer
Most Recent Events
- 28 Oct 2021 No recent reports of development identified for preclinical development in Glioma in Australia (Parenteral)
- 28 Oct 2021 No recent reports of development identified for preclinical development in Glioma(Diagnosis) in Australia (Parenteral)
- 28 Oct 2021 No recent reports of development identified for preclinical development in Ovarian-cancer in Australia (Parenteral)